Access Pharmaceuticals Provides Update on ProLindac Clinical Developme...(inum represents a important improvement ...),Health

Later this month, an Access management and clinical development team is meeting with Access' partner, Aosaikang Medicinal Group (ASK) and several key oncology opinion leaders to finalize plans for ProLindac development in China. In addition, Access is meeting with its Korean partner, JCOM of Seoul, South Korea to finalize development plans in that territory. Access believes that three ProLindac combination trials will start shortly upon regulatory approvals of protocols in both China and Korea. Further, Access has reported receipt of additional milestone payments from its Far East partners in the ordinary course under their collaborative agreements.

"Our Chinese partner, ASK, has made great progress on manufacturing scale-up of ProLindac and advancing the Regulatory process with the SFDA. We are excited about finalizing protocols with ASK and the leading oncologists in China, and look forward to their continued progress," stated Jeffrey B. Davis, Access' President and CEO. "Additionally, we are meeting this month with JCOM and key opinion leaders in Korea, and hope to get the combination trials started in Korea as soon as reasonably possible."

Access intends to design all clinical studies of ProLindac in accordance with FDA standards and intends to use the clinical data from all three planned clinical trials in the Far East to further development in North America and Europe. Access has the right to all clinical data generated in the Far East under the agreements entered into with their Far East partners, and as previously announced, believes that these trials run by its ProLindac partners will save Access between $20 and $30 million in clinical development expenses.

Access is currently in discussion with potential partners for
'/>"/>